Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

The Lancet Infectious Diseases - Tập 15 Số 3 - Trang 301-309 - 2015
Matthew R. Moore1, Ruth Link‐Gelles2, William Schaffner3, Ruth Lynfield4, Catherine Lexau4, Nancy M. Bennett5, Susan Petit6, Shelley Zansky7, Lee H. Harrison8, Arthur Reingold9, Lisa A. Miller10, Karen Scherzinger11, Ann Thomas12, Monica M. Farley13, Elizabeth R. Zell14, Thomas H. Taylor2, Tracy Pondo2, Loren Rodgers2, Lesley McGee2, Bernard Beall2, James H. Jorgensen15, Cynthia G. Whitney2
1National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: [email protected].
2National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
3Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
4Minnesota Department of Health, St Paul, MN, USA
5Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
6Connecticut Department of Public Health, Hartford, CT USA
7New York State Department of Health, Albany, NY, USA.
8Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA
9California Emerging Infections Program, Oakland, CA, USA; School of Public Health, Department of Epidemiology, University of California, Berkeley, CA, USA.
10Colorado Department of Public Health and Environment, Denver, CO, USA
11Institute for Public Health, University of New Mexico, Emerging Infections Program, Albuquerque, NM, USA
12Oregon Public Health Division and Oregon Emerging Infections Program, Portland, OR, USA
13Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Infection Disease Section, Medical Specialty Care Service Line, Atlanta VA Medical Center, Atlanta, GA, USA.
14National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Stat-Epi Associates, Ponte Vedra Beach, FL, USA.
15Department of Pathology, University of Texas Health Science Center, San Antonio, TX, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

2000, Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep, 49, 1

Pilishvili, 2010, Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine, J Infect Dis, 201, 32, 10.1086/648593

Grijalva, 2006, National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States, Pediatrics, 118, 865, 10.1542/peds.2006-0492

Griffin, 2013, U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination, N Engl J Med, 369, 155, 10.1056/NEJMoa1209165

Feikin, 2013, Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites, PLoS Med, 10, e1001517, 10.1371/journal.pmed.1001517

Huang, 2011, Healthcare utilization and cost of pneumococcal disease in the United States, Vaccine, 29, 3398, 10.1016/j.vaccine.2011.02.088

2010, Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children—Advisory Committee on Immunization Practices (ACIP), 2010, MMWR Morb Mortal Wkly Rep, 59, 258

2013, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Morb Mortal Wkly Rep, 62, 521

Park, 2008, Differential effects of pneumococcal vaccines against serotypes 6A and 6C, J Infect Dis, 198, 1818, 10.1086/593339

2011

2012, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Morb Mortal Wkly Rep, 61, 816

Tomczyk, 2014, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Morb Mortal Wkly Rep, 63, 822

2010, Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep, 59, 1

Dagan, 2013, Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial, Clin Infect Dis, 57, 952, 10.1093/cid/cit428

2012, National, state, and local area vaccination coverage among children aged 19–35 months—United States, 2011, MMWR Morb Mortal Wkly Rep, 61, 689

Cohen, 2012, Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media, Pediatr Infect Dis J, 31, 297, 10.1097/INF.0b013e318247ef84

Simonsen, 2014, Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis, Lancet Respir Med, 2, 387, 10.1016/S2213-2600(14)70032-3

Kaplan, 2013, Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine, Pediatr Infect Dis J, 32, 203, 10.1097/INF.0b013e318275614b

Andrews, 2014, Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study, Lancet Infect Dis, 14, 839, 10.1016/S1473-3099(14)70822-9

2012

Steens, 2013, Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway, Vaccine, 31, 6232, 10.1016/j.vaccine.2013.10.032

Hampton, 2012, Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines, J Infect Dis, 205, 401, 10.1093/infdis/jir755

Hanquet, 2011, Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges, Vaccine, 29, 2856, 10.1016/j.vaccine.2011.02.016

Miller, 2011, Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study, Lancet Infect Dis, 11, 760, 10.1016/S1473-3099(11)70090-1

Hausdorff, 2005, Epidemiological differences among pneumococcal serotypes, Lancet Infect Dis, 5, 83, 10.1016/S1473-3099(05)70083-9

Harboe, 2014, Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality, Clin Infect Dis, 59, 1066, 10.1093/cid/ciu524

Thông tin
Thông tin xuất bản

The Lancet Infectious Diseases

Tập 15 Số 3

301-309

Thông tin tác giả